Alvotecha public limited company (anonimous society)incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg, and in Iceland the company is registered with the Icelandic register. No. 671221-9740 (“Company” Where “Alvotech”), published a description of the company in connection with a proposed listing of the company’s common stock (“Shares”) on the Nasdaq First North Growth Market in Iceland (“First North” Where “First North Iceland”).
An application has been filed to list and admit all of the Shares to trading under the symbol ALVO. The ISIN number of the shares is LU2458332611. The total number of shares issued by the Company is 243,649,505, each share having a par value of $0.01.
The first day of trading on First North should be June 23, 2022. Nasdaq Iceland hf. will publish a market notice one day before the first scheduled day of trading on First North.
The Company was listed on Nasdaq Stock Exchange (“Nasdaq United States“) on June 16, 2022. The Company is therefore dual listed on the Nasdaq US and First North. Prior to such listing, there was no public market for the Shares and the Company will not offer any shares to the public in an initial public offering (IPO) prior to the listing of the Shares on First North . The company description has been prepared solely in connection with the listing of the company’s shares on First North Iceland and may not be used for any other purpose.
Following the publication of the company description, all conditions for admission of the shares to trading on First North have been met.
The company description can be found on the company’s website: https://investors.alvotech.com/prospectus
Alvotech is a biotechnology company, founded by Robert Westmanfocused solely on developing and manufacturing biosimilar medicines for patients worldwide. Alvotech, which has approximately 800 employees, seeks to be a global leader in the biosimilars space by providing high-quality, cost-effective products and services enabled by a fully integrated approach and extensive in-house capabilities. Biosimilars are therapeutic equivalents of biologics, a rapidly growing class of highly effective drugs that offer lower cost alternatives to more expensive originator drugs. Alvotech’s current pipeline contains eight biosimilar candidates for the treatment of autoimmune diseases, ocular disorders, osteoporosis, respiratory diseases and cancer. This pipeline targets a total addressable market of more than $85 billion based on IQVIA’s estimated maximum sales of the Reference Products. Alvotech has formed a network of strategic business partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, Chinaand other Asian countries and large parts of South America, Africa and the Middle East. For more information about the Company, please visit www.alvotech.com.
Nasdaq Premier North
Nasdaq First North is regulated as a multilateral trading facility, operated by the various exchanges within Nasdaq Nordic. It has no legal status as EU regulated market. Nasdaq First North companies are subject to Nasdaq First North rules and not to statutory requirements for admission to trading on a regulated market. The risk of such an investment may be higher than in the main market.
Landsbankinn Corporate Finance acted as certified advisor to Alvotech in the preparation and execution of the listing. Landsbankinn holds a business license to operate as a commercial bank under the Icelandic Financial Companies Act, No. 161/2002, and is regulated by the Financial Supervisory Authority of the Central Bank of Iceland. Landsbankinn is approved by Nasdaq Iceland as First North Certified Adviser. Alvotech has elected to undergo full market surveillance after the shares are admitted to trading, meaning it will not have a certified adviser at all times.
©OMX, source GlobeNewswire – EU Press Releases